يعرض 1 - 20 نتائج من 120 نتيجة بحث عن '(( ct ((largest decrease) OR (marked decrease)) ) OR ( 9 026 decrease ))', وقت الاستعلام: 0.41s تنقيح النتائج
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6

    Data Sheet 1_Empagliflozin’s cardioenergetic protective effects through PPARα pathway modulation in heart failure.pdf حسب Hua Wei (60877)

    منشور في 2025
    "…Post-treatment, MRGlu and glucose uptake decreased markedly in the empagliflozin (EMPG) group, while no significant changes were observed in the fenofibrate (FF) group. …"
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15

    (A-H). Case 1: primary subcutaneous facial alveolar echinococcosis. حسب Louis Bohard (22250661)

    منشور في 2025
    "…<p><b>(A)</b> Left frontal swelling at diagnosis. <b>(B)</b> Marked regression of the lesion after 6 months of albendazole therapy. …"
  16. 16
  17. 17

    Table 9_A population-based analysis of the global burden of epilepsy across all age groups (1990–2021): utilizing the Global Burden of Disease 2021 data.xlsx حسب Ling-zhi Yang (20418434)

    منشور في 2024
    "…From 1990 to 2021, the number of epilepsy-related deaths and DALYs both decreased. However, the ASPR of epilepsy increased by about 6.9% (95% UI: −0.10–0.26), and the ASIR increased by almost 12% (95% UI: 0.05–0.33). …"
  18. 18

    Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. حسب Yasuyuki Sotani (20114144)

    منشور في 2025
    "…CRT in the recurrence group significantly decreased from 546.1 ± 117.0 μm preoperatively to 317.1 ± 46.9, 317.8 ± 55.6, 290.8 ± 33.5, 342.9 ± 82.2, 333.0 ± 84.2, and 349.8 ± 76.9 μm at 1, 3, 6, 12, 24, and 36 months postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …"
  19. 19
  20. 20

    Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... حسب Alessandro Colletta (1509928)

    منشور في 2025
    "…</p>Results<p>At baseline, the two groups were comparable in GFR (SGLT2i: 55.6 ± 1.9 vs. insulin: 58.1 ± 2.1 mL/min/1.73 m², p = 0.37), CKD stage, ARFI-SWV (2.9 ± 0.1 vs. 2.8 ± 0.1 m/s, p = 0.26), MELD-Na, and MELD 3.0. …"